Head of Research and Development
A Plasma-Based “Hyperimmune” for COVID-19
The goal of a new alliance is an unbranded immunoglobulin medicine that can be manufactured at scale.
Celebrating an Expanded R&D Facility in Pasadena
CSL Behring site includes three labs and cell manufacturing space near leading academic institutions.